27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has announced results from a new analysis examining obeticholic acid's (OCA) potential to improve transplant-free survival in patients with primary biliary cholangitis (PBC).
- In the analysis, 209 patients treated with OCA in the POISE long-term safety extension study had significantly greater transplant-free survival than patients in the external control groups.
- In the OCA arm, three events were observed versus 146 and 276 occurrences in the Global PBC and UK-PBC external control cohorts, respectively.
- The hazard ratio favoring OCA was 0.20 in Global PBC and 0.28 in UK-PBC in a weighted analysis.
- Thus, patients treated with OCA had a 72% to 80% lower risk of death or liver transplant than the control groups at any time during follow-up.
- Price Action: ICPT shares are down 0.68% at $18.91 during the market session on the last check Monday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!